The size of the cancer immunotherapy market in Europe was worth USD 20.92 Billion in 2020 and estimated to reach USD 37.62 Billion by the end of 2025 with a growing potential of 12.45 %.
Increasing prevalence of cancer, changing lifestyle, excess intake of alcohol and smoking, high efficiency of immunotherapy when compared to other treatments, few side effects associated with cancer immunotherapy that reduce the chance of recurrence of cancer are the factors that drive the Europe cancer immunotherapy market.
A mounting number of cancer patients and rising old people population also drive market growth. The rising commonness of cancer is even driving the European Cancer Immunotherapy Market growth. Numerous healthcare facilities and various national government fund schemes are expected to drive the cancer immunotherapy market in Europe.
Factors like the high cost of immunotherapy treatment and the high reducing rate of the product development cycle are the factors hampering the market growth. The time is also one of the factors that are hampering the regional market boom.
Increasing opportunities in the existing markets and immunotherapy as an alternative to chemotherapy for the first-line treatment are going to be market drivers in the future. Treatment-Free Survival (TFS) provides an essential opportunity for patients and their families to resume their activities, travel, and generally approach their daily lives free from ongoing cancer treatment.
Another opportunity is patients in their last-stage face the possibility of dying from cancer often value to receive a novel therapy that offers potential for long-term disease control in a small percentage of patients.
The cost of cancer therapy treatment and the availability of very little information are the factors challenging the European market. Another problem is disturbing the immune balance intending to restore the potent anti-tumor response that might induce resistance.
Still, many challenges exist and have to overcome to make it available to the cancer patients who need immune intervention.
This research report has been segmented & sub-segmented into the following categories:
Europe is the second-largest market share in the global immunotherapy market and holds positive growth along the foreseen period and is supposed to reach a 12.45% growth rate by the end of 2024. This region is presumed to witness a noticeable increase in the upcoming years. In Europe, Germany is the most prominent market which is driving the area and is assumed to experience a growth rate of about 9% in 2024.
The Europe market is becoming apparent rapidly due to the increasing number of cancer patients in this region. The rapid increase of advance treatment facilities paired up with the availability of skilled professionals and support from the government for R&D further boosts the regional business.
Key market participants in the European cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp, Immunomedics.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Introduction
5.1.2 Breast
5.1.3 Lung
5.1.4 Melanoma
5.1.5 Colorectal
5.1.6 Head & Neck
5.1.7 Prostate
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Application
5.1.10 Market Attractiveness Analysis, By Application
5.1.11 Market Share Analysis, By Application
5.2 Product Type
5.2.1 Introduction
5.2.2 Monoclonal Antibodies
5.2.3 Checkpoint inhibitors/immune modulators
5.2.4 Therapeutic cancer vaccines
5.2.5 Oncolytic virus immunotherapy
5.2.6 Cytokines
5.2.7 Adoptive T cell transfer
5.2.8 Adjuvant Immunotherapy
5.2.9 Interferons
5.2.10 Interleukins
5.2.11 BCG
5.2.12 Others
5.2.13 Y-o-Y Growth Analysis, By Product Type
5.2.14 Market Attractiveness Analysis, By Product Type
5.2.15 Market Share Analysis, By Product Type
5.3 Mode of Administration
5.3.1 Introduction
5.3.2 Intravenous
5.3.3 Oral
5.3.4 Topical
5.3.5 Intra Vesical
5.3.6 Y-o-Y Growth Analysis, By Mode of Administration
5.3.7 Market Attractiveness Analysis, By Mode of Administration
5.3.8 Market Share Analysis, By Mode of Administration
5.3 End users
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Y-o-Y Growth Analysis, By End users
5.3.5 Market Attractiveness Analysis, By End users
5.3.6 Market Share Analysis, By End users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Product Type
6.1.3.4 By Mode of Administration
6.1.3.5 By End users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Product Type
6.1.4.4 By Mode of Administration
6.1.4.5 By End users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Product Type
6.1.5.4 By Mode of Administration
6.1.5.6 By End users
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen
8.3 Viralytics
8.4 Novartis Pharmaceuticals Corporation
8.5 Pfizer
8.6 GlaxoSmithKline Pharmaceuticals Limited
8.7 AstraZeneca plc
8.8 Medivation
8.9 Advaxis
8.10 Bristol-Myers Squibb
8.11 Merck & Co. and Celgene Corp
8.12 Immunomedics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
